STOCK TITAN

StageZero Life Sciences Ltd - SZLSF STOCK NEWS

Welcome to our dedicated news page for StageZero Life Sciences (Ticker: SZLSF), a resource for investors and traders seeking the latest updates and insights on StageZero Life Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect StageZero Life Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of StageZero Life Sciences's position in the market.

Rhea-AI Summary
StageZero Life Sciences, faces a setback as the Ontario Securities Commission denies the Company's application for a voluntary management cease trade order due to anticipated delays in filing financial statements. The Company is working to file the required documents by May 31, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
StageZero Life Sciences, announces a delay in filing audited financial statements for 2023 due to financial resource constraints. Despite the delay, the company expects Q4 2023 revenue to be consistent with previous quarters. The company plans to file its Annual Report on Form 20-F within the U.S. deadline and release financial results by May 31, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
StageZero Life Sciences (TSX:SZLS) announced its third quarter financial results, showcasing $2.2 million in cancer testing and treatment revenue for the nine months ended September 30, 2023. The company has been building partnerships to expand its reach, including agreements with major cancer centers in Toronto and other prospective clinical studies. A recent partnership with My One Medical Source will allow StageZero to offer its diagnostics and treatment protocols to MOMS' national customer base, significantly broadening its market penetration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF) announces a partnership with My One Medical Source to offer its suite of diagnostics and treatment protocols to MOMS' national customer base. The company's first and only mRNA multi-cancer diagnostic for screening for multiple cancers from a single blood sample, Aristotle, and an oncologist-led adjunctive treatment protocol, METRICS study, are expected to be promoted actively by MOMS. The partnership aims to enhance visibility and engage with healthcare providers, employers, and patients across the USA. With the US cancer screening market valued at $77.4 billion and a CAGR of 7%, this collaboration holds significant potential in addressing the economic burden associated with cancer care and improving early diagnosis rates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
-
Rhea-AI Summary
StageZero Life Sciences, Ltd. partners with WellnessScript to provide mental health support for cancer patients, aiming to improve the early detection and management of cancer and other chronic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
none
-
Rhea-AI Summary
StageZero Life Sciences announces partnership with The Source Functional Nutrition to offer nutritional guidance to cancer patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.86%
Tags
StageZero Life Sciences Ltd

OTC:SZLSF

SZLSF Rankings

SZLSF Stock Data

3.59M
95.53M
19.99%
In-Vitro Diagnostic Substance Manufacturing
Manufacturing
Link
Canada
Richmond Hill